Trial Profile
A Phase 1, Randomized, Open-Label, 2-Way Crossover Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of Tofacitinib Following Single Oral Dose Of MR 11 mg Compared To MR 22 mg In Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jan 2013
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Dry eyes; Plaque psoriasis; Psoriatic arthritis; Renal transplant rejection; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 21 Dec 2012 New trial record
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.